Infectious Diseases Research

Below are current clinical trials.

273 studies in Infectious Diseases Research
(all studies, either open or closed).

Filter this list of studies by location, status and more.

1. A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

   Rochester, Minn.

   The purpose of the study is to determine if overall mortality is affected one year after a hematopoietic stem cell transplant (HCT) in patients given a vaccine to prevent cytomegalovirus (CMV). Safety of ASP0113 in subjects undergoing allogeneic HCT will also be evaluated.

2. A Study to Analyze Algorithms for Evaluating Early Detection of SARS-CoV/COVID-19 Infection in Critical Service Employees

   Rochester, Minn.

   The purpose of this study is to develop algorithms that will enable earlier identification and testing triggers for COVID-19 in otherwise asymptomatic patients, and to identify baseline characteristics from patients that ultimately test positive for COVID-19 that may predict clinical trajectory during the evolution of disease.

    

3. Fresh Versus Frozen Stool for Fecal Transplant in Children

   Rochester, Minn.

   The primary goal of this study will be to assess whether stool collected and frozen from anonymous screened unrelated donors can be as effective as stool freshly collected from recipient's parents when used in Fecal Microbial Transplant for the eradication of recurrent Clostridium difficile infections in children. In the current protocols, which are more than 90% effective, each child who is receiving a fecal transplant has to provide their own donor stool, usually from a parent or close relative. This requires considerable screening costs for each case and is logistically complicated as the donor must be present and must stool just prior to the transplant. The investigators hope to show that a small number of healthy donors can provide stool samples which can be frozen and banked and then thawed for use in numerous patients. The primary goal is to show that Clostridium difficile will be eradicated as effectively (Greater than 90% success) when using the stool from the frozen donors.

   The study will also evaluate the inflammatory response and intestinal microbiome in young children aged 1-3 years with Clostridium difficile infections to better predict which ones will respond to fecal transplantation and which ones have incidental infections. For this question the investigators will gather stool samples to check for lactoferrin, calprotectin, and alpha1antitrypsin, and 16s ribosomal RNA analysis in children before and after the fecal transplants. The goal is to see if there is an intestinal microbiome that predisposes some children to getting sick from Clostridium difficile versus just having it incidentally.

4. A Study to Compare the Effectiveness and Safety of ABT-493/ABT-530 to Sofosbuvir Given Together with Declatasvir in Adults with a Chronic Hepatitis C Virus Infection

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to compare the safety and effectiveness of using ABT-493/ABT-530, to the combination of sofosbuvir and daclatasvir in treating adults with genotype 3 chronic hepatitis C virus infection.

5. An Extension of a Previous Study Evaluating the Use of SER-109 to Prevent Recurrent Clostridium Difficile Infections

   Rochester, Minn.

   The purpose of this study is to extend the previous SERES-004 study in patients who had a recurrence of clostridium difficile infection within the first 8 weeks of participation.  

6. A Study of Stool Microbiome, Pathogens, and Infectious Agents Among Olympic Athletes Before and After Participation in Brazil Games

   Rochester, Minn.

   The purpose of this study is to investigate disease causing and other organisms which athletes may be exposed to while participating in the Summer Olympic Games. The study will also investigate the organism and metabolism environment of stool, blood analysis and presence of abnormal cell structures in Olympic athletes in comparison with other elite athletes.

7. Outcomes following treatment of the infected Achilles tendon

   Rochester, Minn.

   Achilles tendon rupture is a common injury and surgical treatment poses the risk of infection. An infected Achilles tendon is a difficult entity to treat due to a thin surrounding soft tissue envelope as well as poor tendon vascularity. In this retrospective review of cases examined at Mayo Clinic-Rochester, we seek to elucidate the clinical outcomes of patients who have undergone treatment for an infected Achilles tendon. 

8. Efficacy, Safety, and Tolerability of Oral Full-Spectrum Microbiota® (CP101) in Subjects with Recurrence of Clostridium difficile Infection (PRISM3)

   Scottsdale/Phoenix, Ariz.

   This is a Multicenter, Double-Blind, Parallel-Arm, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Oral Full-Spectrum Microbiota® (CP101) in Subjects with Recurrence of Clostridium difficile Infection (PRISM3)

9. A Study to Evaluate the Safety, Effectiveness, and Tolerability of Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrent C. Diff

   Rochester, Minn.

   The purpose of this study is to evaluate the effectiveness, safety and tolerability of Oral Full-Spectrum MicrobiotaTM (CP101) in subjects with recurrence of Clostridium difficile infection.

    

    

10. A Study to Assess Monoclonal B-cell Lymphocytosis in Individuals with Chronic Hepatitis C

    Rochester, Minn.

    The purpose of this study is to:

    1. To determine the prevalence of MBL in patients with chronic hepatitis C who are to begin therapy with DAA, and compare with clinic controls who are seen in the general medicine clinic at Mayo Clinic

    2. To determine the correlation between the specific subtype of MBL (CD5- MBL, atypical CLL-phenotype MBL and CLL-phenotype MBL) relative to the HCV genotype

    3. To assess the proportion of individuals with MBL who have an improvement in the circulating monoclonal B-cell population following therapy with DAA